Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…